[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100611584":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":13,"locations":22,"responsibleParty":40,"collaborators":7,"id":44,"slug":45,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":7,"eligibilityCriteria":50,"healthyVolunteers":46,"sex":51,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":7,"studyType":57,"phases":7,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":67,"whyStopped":7,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"The First Affiliated Hospital of Soochow University","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DIAGNOSTIC_TEST","Preoperative Peripheral Blood Immune Marker Analysis.","Preoperative collection of approximately 5 mL peripheral blood via venipuncture, followed by isolation of peripheral blood mononuclear cells (PBMCs) using Ficoll density gradient centrifugation. PBMCs are analyzed via multiparametric flow cytometry on a BD FACSCanto II system to quantify antigen-specific effector T cells (ETASTs, co-expressing CD137 and IFN-γ after ex vivo stimulation with NSCLC antigen peptide pools like NY-ESO-1 and MAGE-A3) and the effector T cell to regulatory T cell ratio (Teff\u002FTreg, with Teff as CD4+\u002FCD8+ expressing IFN-γ\u002FTNF-α\u002FIL-2 and Treg as CD4+CD25+FoxP3+). Analysis uses FlowJo software, targeting 100,000 events per sample. This non-invasive prognostic assessment is distinct from routine clinical blood tests by its focus on tumor-specific immune activation and balance, without therapeutic intent or alteration of standard care.",[14,19],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Mi Liu","CONTACT","86-0512-67972216","mi.liu831116@icoud.com",{"name":20,"role":16,"phone":17,"phoneExt":7,"email":21},"Jun Zhao","zhaojia0327@126.com",[23],{"facility":24,"status":7,"city":25,"state":26,"zip":7,"country":27,"countryCode":28,"cosmosGeoPoint":29,"geoPoint":34,"contacts":35},"Soochow university, Suzhou, Jiangsu 215000","Suzhou","Jiangsu","China","CN",{"type":30,"coordinates":31},"Point",[32,33],120.59538,31.30408,{"lat":33,"lon":32},[36],{"name":37,"role":16,"phone":38,"phoneExt":7,"email":39},"Jiashan Zhu","86+18652808112","zjs18652808112@163.com",{"type":41,"investigatorFullName":42,"investigatorTitle":43,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"SPONSOR_INVESTIGATOR","Zhao Jun","Thoracic Surgery","100611584","circulating-immune-markers-for-prognostic-evaluation-in-postoperative-lung-cancer-patients-100611584",false,"NCT07242482","Circulating Immune Markers for Prognostic Evaluation in Postoperative Lung Cancer Patients","Study on the Clinical Value of Circulating Immune Markers in Prognostic Evaluation of Postoperative Lung Cancer Patients","Inclusion Criteria:\n\n* Age 18 to 80 years.\n* Diagnosed with primary non-small cell lung cancer (NSCLC) and scheduled to undergo curative lung resection at the Department of Thoracic Surgery of our institution.\n* Postoperative pathological stage is IB (with tumor size \\>4cm or high-risk factors: poor differentiation, vascular invasion, visceral pleural invasion, sub-lobar resection, etc.), IIA, IIB, or IIIB (according to the AJCC 8th edition).\n* ECOG performance status of 0 or 1.\n* Voluntarily signs the informed consent form.\n\nExclusion Criteria:\n\n* Received any neoadjuvant therapy prior to surgery.\n* History of other active malignancies.\n* Diagnosed with severe autoimmune diseases, active infections, or immunodeficiency disorders.\n* Presence of severe cardiac, hepatic, or renal dysfunction.\n* Pregnant or lactating women.","ALL","18 Years","80 Years",{"count":55,"type":56},200,"ESTIMATED","OBSERVATIONAL","Investigating the Clinical Value of Tumor Antigen-Specific T Cells and Immune Cell Balance in Peripheral Blood of Non-Small Cell Lung Cancer Patients for Prognostic Evaluation.",[60,61],"Lung Cancer (Diagnosis)","Biomarkers \u002F Blood",[63,64,65,66],"Peripheral Blood","Tumor antigen specific T cells","Teff\u002FTreg ratio","Prognostic Evaluation","NOT_YET_RECRUITING","2025-11-17",{"date":70,"type":71},"2025-11-21","ACTUAL",{"date":73,"type":56},"2025-12-17",{"date":75,"type":56},"2029-12-31",{"name":42,"class":6},1]